Therapeutically exploiting STAT3 activity in cancer — using tissue repair as a road map

The tightly orchestrated temporal and spatial control of signal transducer and activator of transcription 3 (STAT3) activity in epithelial, immune and stromal cells is critical for wound healing and tissue repair. Excessive STAT3 activation within cancer cells and cells of the tumour microenvironment can be viewed as a neoplastic mimic of an inflammation-driven repair response that collectively promotes tumour progression. In addition to the canonical transcriptional pathways by which STAT3 promotes stem cell-like characteristics, survival, proliferation, metastatic potential and immune evasion, cytoplasmic STAT3 activity fuels tumour growth by metabolic and other non-transcriptional mechanisms. Here, we review the tumour-modulating activities of STAT3 in light of its role as a signalling node integrating inflammatory responses during wound healing. Accordingly, many of the cytokines that contribute to the para-inflammatory state of most solid malignancies converge on and underpin dysregulated STAT3 activity. Targeting of these cytokines, their cognate receptors and associated signalling cascades in clinical trials is beginning to demonstrate therapeutic efficacy, given that interference with STAT3 activity is likely to simultaneously curb the growth of cancer cells and augment antitumour immunity.This Review discusses how excessive signal transducer and activator of transcription 3 (STAT3) activation within cancer cells and cells of the tumour microenvironment can be viewed as a neoplastic mimic of an inflammation-driven repair response that promotes tumour progression.

[1]  M. Augsten Cancer-Associated Fibroblasts as Another Polarized Cell Type of the Tumor Microenvironment , 2014, Front. Oncol..

[2]  J. Bromberg,et al.  Touched and Moved by STAT3 , 2006, Science's STKE.

[3]  H. Zhang,et al.  STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. , 2013, The Journal of clinical investigation.

[4]  H. Dvorak Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. , 1986, The New England journal of medicine.

[5]  J. Turkson,et al.  A STAT3-mediated metabolic switch is involved in tumour transformation and STAT3 addiction , 2010, Aging.

[6]  Guangxu Jin,et al.  Interaction between STAT3 and GLI1/tGLI1 oncogenic transcription factors promotes the aggressiveness of triple-negative and HER2-enriched breast cancers , 2017, Oncogene.

[7]  C. Datz,et al.  Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth , 2012, Nature.

[8]  E. Yeh,et al.  SUMOylation and SENP3 regulate STAT3 activation in head and neck cancer , 2016, Oncogene.

[9]  A. Butte,et al.  Widespread parainflammation in human cancer , 2016, Genome Biology.

[10]  Kuen-Feng Chen,et al.  Discovery of novel src homology region 2 domain‐containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma , 2014, Hepatology.

[11]  J. Darnell,et al.  Essential Role of STAT3 in Postnatal Survival and Growth Revealed by Mice Lacking STAT3 Serine 727 Phosphorylation , 2004, Molecular and Cellular Biology.

[12]  Can Alkan,et al.  Activating mutations of STAT5B and STAT3 in lymphomas derived from gamma delta-T or NK cells , 2022 .

[13]  Fiona M. Watt,et al.  Epithelial stem cells, wound healing and cancer , 2012, Nature Reviews Cancer.

[14]  O. Sieber,et al.  Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically. , 2013, Cancer cell.

[15]  N. Reich,et al.  STAT3 is a master regulator of epithelial identity and KRAS-driven tumorigenesis , 2018, Genes & development.

[16]  S. Snapper,et al.  Anti-inflammatory effect of IL-10 mediated by metabolic reprogramming of macrophages , 2017, Science.

[17]  S. Rose-John,et al.  The role of IL-6 in host defence against infections: immunobiology and clinical implications , 2017, Nature Reviews Rheumatology.

[18]  I. Noth,et al.  PD-1 up-regulation on CD4+ T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-β1 production , 2018, Science Translational Medicine.

[19]  M. Dietrich,et al.  STAT3 inhibition of gluconeogenesis is downregulated by SirT1 , 2009, Nature Cell Biology.

[20]  L. Zitvogel,et al.  STAT3 Inhibition Enhances the Therapeutic Efficacy of Immunogenic Chemotherapy by Stimulating Type 1 Interferon Production by Cancer Cells. , 2015, Cancer research.

[21]  W. Alexander,et al.  General Nature of the STAT3-Activated Anti-Inflammatory Response1 , 2006, The Journal of Immunology.

[22]  B. Becher,et al.  Epithelial IL-23R Signaling Licenses Protective IL-22 Responses in Intestinal Inflammation. , 2016, Cell reports.

[23]  J. Turkson,et al.  Constitutively active Stat3 enhances neu-mediated migration and metastasis in mammary tumors via upregulation of Cten. , 2010, Cancer research.

[24]  R. Balaban,et al.  Stoichiometry of STAT3 and Mitochondrial Proteins , 2010, The Journal of Biological Chemistry.

[25]  J. Pollard,et al.  Targeting macrophages: therapeutic approaches in cancer , 2018, Nature Reviews Drug Discovery.

[26]  Hua Yu,et al.  CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells. , 2014, The Journal of clinical investigation.

[27]  M. Goldsmith,et al.  STAT3 governs distinct pathways in emergency granulopoiesis and mature neutrophils. , 2006, Blood.

[28]  J. Darnell,et al.  Maximal activation of transcription by statl and stat3 requires both tyrosine and serine phosphorylation , 1995, Cell.

[29]  G. Stark,et al.  STAT3-driven transcription depends upon the dimethylation of K49 by EZH2 , 2015, Proceedings of the National Academy of Sciences.

[30]  M. Neurath,et al.  STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing , 2009, The Journal of experimental medicine.

[31]  Xinbing Sui,et al.  The role of STAT3 in autophagy , 2015, Autophagy.

[32]  S. Heymans,et al.  STAT3 activity is necessary and sufficient for the development of immune-mediated myocarditis in mice and promotes progression to dilated cardiomyopathy , 2013, EMBO molecular medicine.

[33]  Fei Xing,et al.  Cancer associated fibroblasts (CAFs) in tumor microenvironment. , 2010, Frontiers in bioscience.

[34]  V. Poli,et al.  STAT3 localizes to the ER, acting as a gatekeeper for ER-mitochondrion Ca2+ fluxes and apoptotic responses , 2018, Cell Death & Differentiation.

[35]  V. Sanz-Moreno,et al.  Epigenetic switch drives the conversion of fibroblasts into proinvasive cancer-associated fibroblasts , 2015, Nature Communications.

[36]  Alex J. Walsh,et al.  Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer. , 2015, Gastroenterology.

[37]  D. Scheuner,et al.  Regulation of starvation- and virus-induced autophagy by the eIF2α kinase signaling pathway , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[38]  G. Stark,et al.  Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. , 2007, Genes & development.

[39]  Q. Cai,et al.  Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia. , 2016, Blood.

[40]  S. Mustjoki,et al.  Somatic STAT3 mutations in large granular lymphocytic leukemia. , 2012, The New England journal of medicine.

[41]  R. Jove,et al.  Hyperactivation of STAT3 Is Involved in Abnormal Differentiation of Dendritic Cells in Cancer , 2004, The Journal of Immunology.

[42]  Jing Ma,et al.  Regulation of Stat3 nuclear import by importin α5 and importin α7 via two different functional sequence elements , 2006 .

[43]  V. Poli,et al.  STAT3-Mediated Metabolic Reprograming in Cellular Transformation and Implications for Drug Resistance , 2015, Front. Oncol..

[44]  Chuang Zhou,et al.  The Correlation Between the Immune and Epithelial-Mesenchymal Transition Signatures Suggests Potential Therapeutic Targets and Prognosis Prediction Approaches in Kidney Cancer , 2018, Scientific Reports.

[45]  Yu Qin,et al.  STAT3-regulated exosomal miR-21 promotes angiogenesis and is involved in neoplastic processes of transformed human bronchial epithelial cells. , 2016, Cancer letters.

[46]  V. Fried,et al.  Cellular Physiology of STAT3: Where’s the Cytoplasmic Monomer?* , 1999, The Journal of Biological Chemistry.

[47]  Hua Yu,et al.  Revisiting STAT3 signalling in cancer: new and unexpected biological functions , 2014, Nature Reviews Cancer.

[48]  P. Jung,et al.  Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation. , 2012, Cancer cell.

[49]  V. Poli,et al.  Stat3 regulates microtubules by antagonizing the depolymerization activity of stathmin. , 2006, The Journal of cell biology.

[50]  Y. E. Chin,et al.  Stat3 Dimerization Regulated by Reversible Acetylation of a Single Lysine Residue , 2005, Science.

[51]  B. Ammori,et al.  Increased Levels of Granulocytic Myeloid-Derived Suppressor Cells in Peripheral Blood and Tumour Tissue of Pancreatic Cancer Patients , 2014, Journal of immunology research.

[52]  P. Rosenstiel,et al.  ADAM17 is required for EGF-R–induced intestinal tumors via IL-6 trans-signaling , 2018, The Journal of experimental medicine.

[53]  N. Gray,et al.  Myeloid ERK5 deficiency suppresses tumor growth by blocking protumor macrophage polarization via STAT3 inhibition , 2018, Proceedings of the National Academy of Sciences.

[54]  S. Rose-John,et al.  Interleukin-6: designing specific therapeutics for a complex cytokine , 2018, Nature Reviews Drug Discovery.

[55]  J. Joyce,et al.  STAT3 and STAT6 Signaling Pathways Synergize to Promote Cathepsin Secretion from Macrophages via IRE1α Activation. , 2016, Cell reports.

[56]  Wenjun Cheng,et al.  Activated Signal Transducer and Activator of Transcription (STAT) 3 , 2004, Cancer Research.

[57]  Ash A. Alizadeh,et al.  Gene Expression Signature of Fibroblast Serum Response Predicts Human Cancer Progression: Similarities between Tumors and Wounds , 2004, PLoS biology.

[58]  K. Rajewsky,et al.  STAT3 Activation in Th17 and Th22 Cells Controls IL-22–Mediated Epithelial Host Defense during Infectious Colitis , 2014, The Journal of Immunology.

[59]  G. Moseley,et al.  The Rabies Virus Interferon Antagonist P Protein Interacts with Activated STAT3 and Inhibits Gp130 Receptor Signaling , 2013, Journal of Virology.

[60]  J. Fagin,et al.  STAT3 negatively regulates thyroid tumorigenesis , 2012, Proceedings of the National Academy of Sciences.

[61]  M. Talpaz,et al.  Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma. , 2018, Blood.

[62]  Daniel Nathans,et al.  Specific Ablation of Stat3β Distorts the Pattern of Stat3-Responsive Gene Expression and Impairs Recovery from Endotoxic Shock , 2002, Cell.

[63]  S. Akira,et al.  Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. , 1999, Immunity.

[64]  Jennifer R. Grandis,et al.  Targeting the IL-6/JAK/STAT3 signalling axis in cancer , 2018, Nature Reviews Clinical Oncology.

[65]  D. Tweardy,et al.  Chemical Probes that Competitively and Selectively Inhibit Stat3 Activation , 2009, PloS one.

[66]  Sami Al-Hajjar,et al.  B cell–intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans , 2010, The Journal of experimental medicine.

[67]  P Jay,et al.  Specific inhibition of Stat3 signal transduction by PIAS3. , 1997, Science.

[68]  K. Kiguchi,et al.  Stat3 binds to mitochondrial DNA and regulates mitochondrial gene expression in keratinocytes , 2014, The Journal of investigative dermatology.

[69]  R. Kalluri The biology and function of fibroblasts in cancer , 2016, Nature Reviews Cancer.

[70]  S. Fuller,et al.  IL-10 Potentiates Differentiation of Human Induced Regulatory T Cells via STAT3 and Foxo1 , 2015, The Journal of Immunology.

[71]  E. Vellenga,et al.  Ser727‐dependent transcriptional activation by association of p300 with STAT3 upon IL‐6 stimulation , 2001, FEBS letters.

[72]  T. Putoczki,et al.  ReviewStat 3 : linking inflammation to epithelial cancer-more than a " gut " feeling ? , 2015 .

[73]  Chin Wee Tan,et al.  Partial inhibition of gp130-Jak-Stat3 signaling prevents Wnt–β-catenin–mediated intestinal tumor growth and regeneration , 2014, Science Signaling.

[74]  Sreenath V. Sharma,et al.  A Chemical Biology Approach to Developing STAT Inhibitors: Molecular Strategies for Accelerating Clinical Translation , 2011, Oncotarget.

[75]  P. Sehgal,et al.  Membrane-associated STAT3 and PY-STAT3 in the Cytoplasm* , 2006, Journal of Biological Chemistry.

[76]  K. Heeg,et al.  PD‐L1 expression on tolerogenic APCs is controlled by STAT‐3 , 2011, European journal of immunology.

[77]  W. Gerald,et al.  Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. , 2007, The Journal of clinical investigation.

[78]  A. Horiguchi,et al.  STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma , 2010, British Journal of Cancer.

[79]  Long-Bang Chen,et al.  Cancer-associated fibroblasts treated with cisplatin facilitates chemoresistance of lung adenocarcinoma through IL-11/IL-11R/STAT3 signaling pathway , 2016, Scientific Reports.

[80]  R. Medzhitov Origin and physiological roles of inflammation , 2008, Nature.

[81]  C. Shiau,et al.  Two novel SHP-1 agonists, SC-43 and SC-78, are more potent than regorafenib in suppressing the in vitro stemness of human colorectal cancer cells , 2018, Cell Death Discovery.

[82]  P. Russell,et al.  IL6 Trans-signaling Promotes KRAS-Driven Lung Carcinogenesis. , 2016, Cancer research.

[83]  Hua Yu,et al.  Stat3-induced S1PR1 expression is critical for persistent Stat3 activation in tumors , 2010, Nature Medicine.

[84]  J. Darnell,et al.  Stat3 as an Oncogene , 1999, Cell.

[85]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[86]  T. Reinheckel,et al.  Mitophagy in Intestinal Epithelial Cells Triggers Adaptive Immunity during Tumorigenesis , 2018, Cell.

[87]  J. O’Shea,et al.  Translational and clinical advances in JAK‐STAT biology: The present and future of jakinibs , 2018, Journal of leukocyte biology.

[88]  K. Müller,et al.  Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells. , 2018, Journal of natural products.

[89]  C. Fielding,et al.  IL-6 Regulates Neutrophil Trafficking during Acute Inflammation via STAT31 , 2008, The Journal of Immunology.

[90]  Jian-Ting Zhang,et al.  Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we? , 2018, Pharmacology & therapeutics.

[91]  J. Darnell,et al.  Stat3 Activation Is Required for Cellular Transformation by v-src , 1998, Molecular and Cellular Biology.

[92]  D. Gabrilovich Mechanisms and functional significance of tumour-induced dendritic-cell defects , 2004, Nature Reviews Immunology.

[93]  Y. Ben-Neriah,et al.  Inflammatory networks underlying colorectal cancer , 2016, Nature Immunology.

[94]  S. Tangye,et al.  Insights into the Role of STAT3 in Human Lymphocyte Differentiation as Revealed by the Hyper-IgE Syndrome1 , 2009, The Journal of Immunology.

[95]  J. Darnell,et al.  Interacting Regions in Stat3 and c-Jun That Participate in Cooperative Transcriptional Activation , 1999, Molecular and Cellular Biology.

[96]  P. Fawcett,et al.  Function of Mitochondrial Stat3 in Cellular Respiration , 2009, Science.

[97]  Massimo Gadina,et al.  The JAK-STAT pathway: impact on human disease and therapeutic intervention. , 2015, Annual review of medicine.

[98]  T. Putoczki,et al.  Molecular Pathways: IL11 as a Tumor-Promoting Cytokine—Translational Implications for Cancers , 2014, Clinical Cancer Research.

[99]  C. Watson,et al.  Stat3 controls cell death during mammary gland involution by regulating uptake of milk fat globules and lysosomal membrane permeabilization , 2014, Nature Cell Biology.

[100]  D. Davar,et al.  Toll-Like Receptor 9 Agonists in Cancer , 2020, OncoTargets and therapy.

[101]  Hua Yu,et al.  Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells , 2004, Nature Medicine.

[102]  Luke Barron,et al.  Macrophages: Master Regulators of Inflammation and Fibrosis , 2010, Seminars in liver disease.

[103]  E. Yang,et al.  The Role of STAT-3 in Cetuximab-induced Radiosensitization in Head-and-Neck Cancer Cells , 2012 .

[104]  L. Nelles,et al.  Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases , 2013, The Journal of Immunology.

[105]  Quin F. Wills,et al.  Structural Remodeling of the Human Colonic Mesenchyme in Inflammatory Bowel Disease , 2018, Cell.

[106]  J. Nemunaitis,et al.  AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer , 2015, Science Translational Medicine.

[107]  C. Burns,et al.  Targeting JAK kinase in solid tumors: emerging opportunities and challenges , 2016, Oncogene.

[108]  Erik Sahai,et al.  ROCK and JAK1 signaling cooperate to control actomyosin contractility in tumor cells and stroma. , 2011, Cancer cell.

[109]  S. Dewilde,et al.  The STAT3 isoforms α and β have unique and specific functions , 2004, Nature Immunology.

[110]  J. Turkson,et al.  Stat3 controls lysosomal-mediated cell death in vivo , 2011, Nature Cell Biology.

[111]  D. Levy,et al.  STAT3 regulated ARF expression suppresses prostate cancer metastasis , 2015, Nature Communications.

[112]  P. Aigner,et al.  STAT3 isoforms: Alternative fates in cancer? , 2019, Cytokine.

[113]  M. Scheulen,et al.  Toll-like receptor 9 agonists as cancer therapeutics , 2011, Expert opinion on investigational drugs.

[114]  L. Kenner,et al.  The dark and the bright side of Stat3: proto-oncogene and tumor-suppressor. , 2009, Frontiers in bioscience.

[115]  R. Jove,et al.  Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. , 2001, Cancer research.

[116]  Hua Yu,et al.  CTLA4 Promotes Tyk2-STAT3-Dependent B-cell Oncogenicity. , 2017, Cancer research.

[117]  Can Alkan,et al.  Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells , 2015, Nature Communications.

[118]  P. Dent,et al.  Mitochondrial Localized Stat3 Promotes Breast Cancer Growth via Phosphorylation of Serine 727* , 2013, The Journal of Biological Chemistry.

[119]  M. Kortylewski,et al.  TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients , 2015, Clinical Cancer Research.

[120]  Ash A. Alizadeh,et al.  Abstract PR09: The prognostic landscape of genes and infiltrating immune cells across human cancers , 2015 .

[121]  M. J. Ruiz,et al.  Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. , 2011, Blood.

[122]  Jing Zhang,et al.  Unique genome-wide map of TCF4 and STAT3 targets using ChIP-seq reveals their association with new molecular subtypes of glioblastoma. , 2013, Neuro-oncology.

[123]  M. Delorenzi,et al.  RIP4 inhibits STAT3 signaling to sustain lung adenocarcinoma differentiation , 2017, Cell Death and Differentiation.

[124]  Christine A Iacobuzio-Donahue,et al.  Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular-fibrosis and tumor progression , 2016, Nature Medicine.

[125]  L. Zitvogel,et al.  STAT3 inhibition for cancer therapy: Cell-autonomous effects only? , 2016, Oncoimmunology.

[126]  Yuli Lin,et al.  FAP Promotes Immunosuppression by Cancer-Associated Fibroblasts in the Tumor Microenvironment via STAT3-CCL2 Signaling. , 2016, Cancer research.

[127]  K. Hess,et al.  A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo , 2007, Oncogene.

[128]  Jeou-Yuan Chen,et al.  Acetylation and activation of STAT3 mediated by nuclear translocation of CD44 , 2009, The Journal of cell biology.

[129]  R. Xiang,et al.  Tumor‐Associated Macrophages Regulate Murine Breast Cancer Stem Cells Through a Novel Paracrine EGFR/Stat3/Sox‐2 Signaling Pathway , 2013, Stem cells.

[130]  D. Nam,et al.  Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. , 2013, Cancer cell.

[131]  G. Stark,et al.  Reversible methylation of promoter-bound STAT3 by histone-modifying enzymes , 2010, Proceedings of the National Academy of Sciences.

[132]  L. Qin,et al.  LncRNA PVT1 promotes angiogenesis via activating the STAT3/VEGFA axis in gastric cancer , 2018, Oncogene.

[133]  E. Casanova,et al.  Stat3 is a negative regulator of intestinal tumor progression in Apc(Min) mice. , 2010, Gastroenterology.

[134]  Hua Yu,et al.  A requirement of STAT3 DNA binding precludes Th-1 immunostimulatory gene expression by NF-κB in tumors. , 2011, Cancer research.

[135]  F. Uckun,et al.  Role of the Leukemia-associated Transcription Factor STAT3 in Platelet Physiology , 2002, Leukemia & lymphoma.

[136]  R. Boidot,et al.  Sirtuin-1 Activation Controls Tumor Growth by Impeding Th17 Differentiation via STAT3 Deacetylation. , 2017, Cell reports.

[137]  S. Akira,et al.  Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway , 1994, Cell.

[138]  S. Akira,et al.  Keratinocyte‐specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis , 1999, The EMBO journal.

[139]  W. Frankel,et al.  Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. , 2013, Cancer research.

[140]  Jongdae Lee,et al.  Signal Transducer and Activator of Transcription 3 (STAT3) Protein Suppresses Adenoma-to-carcinoma Transition in Apcmin/+ Mice via Regulation of Snail-1 (SNAI) Protein Stability* , 2012, The Journal of Biological Chemistry.

[141]  A. Neunkirchner,et al.  STAT3 governs hyporesponsiveness and granzyme B-dependent suppressive capacity in human CD4+ T cells , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[142]  A. D. Panopoulos,et al.  STAT3 controls myeloid progenitor growth during emergency granulopoiesis. , 2010, Blood.

[143]  H. Katabuchi,et al.  Involvement of M2‐polarized macrophages in the ascites from advanced epithelial ovarian carcinoma in tumor progression via Stat3 activation , 2010, Cancer science.

[144]  D. Levy,et al.  Mitochondrial STAT3 Supports Ras-Dependent Oncogenic Transformation , 2009, Science.

[145]  P. Schumacker,et al.  Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles' heel? , 2014, Nature Reviews Cancer.

[146]  Yinghui Zhu,et al.  ANGPTL1 Interacts with Integrin α1β1 to Suppress HCC Angiogenesis and Metastasis by Inhibiting JAK2/STAT3 Signaling. , 2017, Cancer research.

[147]  J. Scheller,et al.  Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. , 2011, The Journal of clinical investigation.

[148]  J. Grandis,et al.  Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer , 2015, PloS one.

[149]  K. Polyak,et al.  Non-cell autonomous tumor-growth driving supports sub-clonal heterogeneity , 2014, Nature.

[150]  M. Tremblay,et al.  Protein Tyrosine Phosphatases, TC-PTP, SHP1, and SHP2, Cooperate in Rapid Dephosphorylation of Stat3 in Keratinocytes Following UVB Irradiation , 2010, PLoS ONE.

[151]  G. Laurent,et al.  Genetic partitioning of interleukin-6 signalling in mice dissociates Stat3 from Smad3-mediated lung fibrosis , 2012, EMBO molecular medicine.

[152]  Wei Liu,et al.  Cancer-associated fibroblasts induce PDL1+ neutrophils through the IL6-STAT3 pathway that foster immune suppression in hepatocellular carcinoma , 2018, Cell Death & Disease.

[153]  Hua Yu,et al.  Tumour immunology: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment , 2007, Nature Reviews Immunology.

[154]  A. Taketomi,et al.  IL-11 induces differentiation of myeloid-derived suppressor cells through activation of STAT3 signalling pathway , 2015, Scientific Reports.

[155]  David E Levy,et al.  Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. , 2008, Genes & development.

[156]  E. Elinav,et al.  IL-22 Deficiency Alters Colonic Microbiota To Be Transmissible and Colitogenic , 2013, The Journal of Immunology.

[157]  Hua Yu,et al.  Activated Signal Transducers and Activators of Transcription 3 Signaling Induces CD46 Expression and Protects Human Cancer Cells from Complement-Dependent Cytotoxicity , 2007, Molecular Cancer Research.

[158]  C. Drake,et al.  Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. , 2009, Cancer cell.

[159]  H. A. Rogoff,et al.  Suppression of cancer relapse and metastasis by inhibiting cancer stemness , 2015, Proceedings of the National Academy of Sciences.

[160]  P. Heinrich,et al.  Principles of interleukin (IL)-6-type cytokine signalling and its regulation. , 2003, The Biochemical journal.

[161]  Ozge Canli,et al.  gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. , 2009, Cancer cell.

[162]  W. Bamlet,et al.  Inflammation-induced NFATc1-STAT3 transcription complex promotes pancreatic cancer initiation by KrasG12D. , 2014, Cancer discovery.

[163]  Riitta Lahesmaa,et al.  Genome-wide Analysis of STAT3-Mediated Transcription during Early Human Th17 Cell Differentiation. , 2017, Cell reports.

[164]  E. O'Duibhir,et al.  The STAT3–IL-10–IL-6 Pathway Is a Novel Regulator of Macrophage Efferocytosis and Phenotypic Conversion in Sterile Liver Injury , 2018, The Journal of Immunology.

[165]  Hua Yu,et al.  Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity , 2005, Nature Medicine.

[166]  L. Galluzzi,et al.  Cytoplasmic STAT3 represses autophagy by inhibiting PKR activity. , 2012, Molecular cell.

[167]  S. Watowich,et al.  STAT3 signaling in immunity. , 2016, Cytokine & growth factor reviews.

[168]  J. Kere,et al.  Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease , 2014, Nature Genetics.

[169]  R. Flavell,et al.  STAT3 is required for Flt3L-dependent dendritic cell differentiation. , 2003, Immunity.

[170]  H. Tamaki,et al.  STAT3 Expression in Host Myeloid Cells Controls Graft-versus-Host Disease Severity. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[171]  Kevin M. McBride,et al.  STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-alpha3. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[172]  D. Levy,et al.  STAT3 supports experimental K-RasG12D-induced murine myeloproliferative neoplasms dependent on serine phosphorylation. , 2014, Blood.

[173]  V. Poli,et al.  Critical role for Stat3 in T-dependent terminal differentiation of IgG B cells. , 2006, Blood.

[174]  L. Hennighausen,et al.  Janus Kinase 1 Is Essential for Inflammatory Cytokine Signaling and Mammary Gland Remodeling , 2016, Molecular and Cellular Biology.

[175]  R. Ahmed,et al.  STAT3, STAT4, NFATc1, and CTCF Regulate PD-1 through Multiple Novel Regulatory Regions in Murine T Cells , 2014, The Journal of Immunology.

[176]  B. Groner,et al.  Jak Stat signaling and cancer: Opportunities, benefits and side effects of targeted inhibition , 2017, Molecular and Cellular Endocrinology.

[177]  Hua Yu,et al.  CD5 Binds to Interleukin-6 and Induces a Feed-Forward Loop with the Transcription Factor STAT3 in B Cells to Promote Cancer. , 2016, Immunity.

[178]  D. Tu,et al.  The NCIC CTG and AGITG CO.23 trial: A phase III randomized study of BBI608 plus best supportive care (BSC) versus placebo (PBO) plus BSC in patients (Pts) with pretreated advanced colorectal carcinoma (CRC). , 2014 .

[179]  N. Nicola,et al.  Inhibition of IL-6 family cytokines by SOCS3. , 2014, Seminars in immunology.

[180]  G. Stark,et al.  Roles of unphosphorylated STATs in signaling , 2008, Cell Research.

[181]  Johannes Zuber,et al.  Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis , 2015, Nature Communications.

[182]  A. Heimberger,et al.  A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. , 2007, Cancer research.

[183]  H. Ochs,et al.  Heterozygous signal transducer and activator of transcription 3 mutations in hyper-IgE syndrome result in altered B-cell maturation. , 2012, The Journal of allergy and clinical immunology.

[184]  S. Akira,et al.  Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[185]  J. Licht,et al.  Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia , 2003, Nature Genetics.

[186]  K. Hwang,et al.  Macrophage PD-L1 strikes back: PD-1/PD-L1 interaction drives macrophages toward regulatory subsets , 2013 .

[187]  R. Banerjee,et al.  Combination of cationic dexamethasone derivative and STAT3 inhibitor (WP1066) for aggressive melanoma: a strategy for repurposing a phase I clinical trial drug , 2017, Molecular and Cellular Biochemistry.

[188]  Hua Yu,et al.  STAT3 in CD8+ T Cells Inhibits Their Tumor Accumulation by Downregulating CXCR3/CXCL10 Axis , 2015, Cancer Immunology Research.

[189]  D. Levy,et al.  Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. , 2005, Cancer research.

[190]  R. Dickins,et al.  Generation of an inducible mouse model to reversibly silence Stat3 , 2017, Genesis.

[191]  J. Ritz,et al.  IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. , 2006, Blood.

[192]  Keshava Rajagopal,et al.  Teaching old receptors new tricks: biasing seven-transmembrane receptors , 2010, Nature Reviews Drug Discovery.

[193]  G. Bepler,et al.  Activated Epidermal Growth Factor Receptor–Stat-3 Signaling Promotes Tumor Survival In vivo in Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[194]  V. Poli,et al.  Loss of STAT3 in murine NK cells enhances NK cell-dependent tumor surveillance. , 2014, Blood.

[195]  Tao Yang,et al.  IL-17 promotes tumor angiogenesis through Stat3 pathway mediated upregulation of VEGF in gastric cancer , 2016, Tumor Biology.

[196]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[197]  M. Neurath,et al.  Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo , 2000, Nature Medicine.

[198]  Hua Yu,et al.  CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells. , 2015, The Journal of clinical investigation.

[199]  B. Jenkins,et al.  Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice , 2002, Nature Medicine.

[200]  J. Zucman‐Rossi,et al.  Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas , 2011, The Journal of experimental medicine.

[201]  S. Mustjoki,et al.  STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. , 2012, Blood.

[202]  Traci M. Blonquist,et al.  Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent. , 2016, Blood.

[203]  J. Darnell,et al.  Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. , 1994, Science.

[204]  A. Giraud,et al.  Altered gp130 signalling ameliorates experimental colitis via myeloid cell-specific STAT3 activation and myeloid-derived suppressor cells , 2016, Scientific Reports.